# IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and…

- Source: PR Newswire
- Published: 2026-10-23T10:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/ide849-shr-4849-dll3-top1-adc-updated-phase-1-results-at-esmo-2026-demonstrates-promising-anti-tumor-activity-and-preliminary-overall-survival-results-in-relapsed-small-cell-lung-cancer-and-neuroendocrine-carcinomas-302917466.html
- Canonical: https://groundlevelnews.com/story/ide849-shr-4849-dll3-top1-adc-updated-phase-1-results-at-esmo-2026-dem-ba0795/

17.4-month median OS in 2L SCLC (n=51) and 14.7-month median OS in 2L + ≥3L SCLC (n=101) 72.5% (37/51) ORR and 60.8% (31/51) cORR in 2L SCLC with 6.9-month median PFS; 68.3% (69/101) ORR and 54.5% (55/101) cORR in 2L + ≥3L SCLC with 6.8-month median PFS 76.9% (20/26) ORR and 65.4% (17/26)...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._